KLRS
Kalaris Therapeutics, Inc.Company Information
- Company Name
- Kalaris Therapeutics, Inc.
- CIK
- CIK0001754068
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- KLRS: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- KLRS
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-05-20
- Last sale
- 2026-03-20
- Shares purchased (TTM)
- 724,147
- Shares sold (TTM)
- 1,915
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 18,011,426
- Shares outstanding
- 23,797,306
- Ownership
- 75.69%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- -1.76%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 43 | 34 | 98 | 42 | 88 | 101 | 2 | 2 | 6 | 5 | 90 | 96 | ||||||
| Short Term Investments | 50 | 63 | 20 | 35 | - | - | 0 | 5 | 25 | 54 | 94 | 118 | ||||||
| Deferred Costs Current | 1 | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 2 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 0 | 1 | 3 | 6 | ||||||
| Interest Receivable Current | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Current | 96 | 98 | 119 | 78 | 92 | 102 | 3 | 123 | 130 | 141 | 188 | 220 | ||||||
| Deferred Costs | - | - | 0 | 0 | 0 | 0 | 3 | - | - | - | - | - | ||||||
| Marketable Securities Noncurrent | - | 8 | - | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 2 | - | - | 0 | - | 0 | 2 | 2 | 25 | ||||||
| Restricted Cash Noncurrent | 1 | 1 | 0 | 1 | 1 | 1 | 0 | - | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | 2 | 2 | 1 | 1 | 1 | 0 | 0 | - | - | - | 0 | 1 | ||||||
| Property Plant And Equipment Net | - | - | - | - | - | - | - | - | - | - | - | 1 | ||||||
| Assets | 100 | 110 | 122 | 81 | 93 | 103 | 6 | 123 | 131 | 144 | 191 | 248 | ||||||
Liabilities Current | ||||||||||||||||||
| Workers Compensation Liability Current | - | - | - | - | - | 0 | - | - | - | - | - | - | ||||||
| Accounts Payable Current | 1 | 1 | 1 | 0 | 4 | 2 | 2 | 0 | 0 | 1 | 7 | 4 | ||||||
| Accrued Liabilities Current | - | - | - | - | - | - | 5 | 1 | 2 | 5 | 10 | 16 | ||||||
| Taxes Payable Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Convertible Notes Payable Current | - | - | 0 | 0 | 0 | 0 | 20 | - | - | - | - | - | ||||||
| Derivative Liabilities Current | - | - | 0 | 0 | 0 | 0 | 1 | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | - | - | 0 | - | 1 | 2 | 11 | 13 | ||||||
| Other Liabilities Current | - | - | - | - | - | - | - | - | - | - | 1 | - | ||||||
| Liabilities Current | 9 | 8 | 10 | 6 | 8 | 7 | 25 | 1 | 2 | 8 | 28 | 33 | ||||||
| Operating Lease Liability Noncurrent | 1 | 1 | 1 | 1 | - | - | 0 | - | 8 | 16 | 17 | 20 | ||||||
| Liabilities | 42 | 41 | 43 | 39 | 40 | 39 | 57 | 1 | 11 | 24 | 45 | 53 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | 0 | 0 | 0 | 0 | 46 | - | - | - | - | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 240 | 239 | 239 | 192 | 191 | 191 | 20 | 818 | 813 | 807 | 802 | 792 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | - | - | 0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -182 | -171 | -160 | -150 | -138 | -127 | -117 | -697 | -693 | -686 | -656 | -596 | ||||||
| Stockholders Equity | 58 | 69 | 79 | 42 | 53 | 64 | -97 | -89 | -52 | -48 | 146 | 195 | ||||||
| Liabilities And Stockholders Equity | 100 | 110 | 122 | 81 | 93 | 103 | 6 | 123 | 131 | 144 | 191 | 248 | ||||||
| Related Party | -0 | 0 | 0 | 0 | -0 | 0 | 0 | - | - | - | 1 | 0 | ||||||
| Debt Instrument Unamortized Discount Current | - | - | - | - | - | - | 1 | - | - | - | - | - | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | 0.00 | 0.00 | 0.00 | - | 0.00 | - | - | - | - | - | ||||||
| Temporary Equity Shares Authorized | - | - | 0 | 0 | 0 | 0 | 75 | - | - | - | - | - | ||||||
| Temporary Equity Shares Issued | - | - | 0 | 0 | 0 | 0 | 43 | - | - | - | - | - | ||||||
| Temporary Equity Shares Outstanding | - | - | 0 | 0 | 0 | 0 | 43 | - | - | - | - | - | ||||||
| Temporary Equity Liquidation Preference | - | - | 0 | 0 | 0 | - | 45 | - | - | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 86 | 300 | 300 | 300 | 150 | 300 | ||||||
| Common Stock Shares Issued | 24 | 23 | 23 | 19 | 19 | 19 | 1 | 115 | 115 | 115 | 5 | 114 | ||||||
| Shares Outstanding | 24 | 23 | 23 | 19 | 19 | 19 | 1 | 115 | 115 | 115 | 5 | 114 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | - | 10 | - | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | - | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | - | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialKalaris Therapeutics, Inc. (KLRS) — SEC Financial Statements & Analysis
Kalaris Therapeutics, Inc. (KLRS) is a biological products, (no diagnostic substances) company, incorporated in DE. Kalaris Therapeutics, Inc. trades on Nasdaq as: KLRS. Kalaris Therapeutics, Inc. (KLRS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Kalaris Therapeutics, Inc. carries a market cap of $96.86M, a P/E ratio of -2.19x, a P/B ratio of 1.68x, an enterprise value of $53.68M, and an EV/EBITDA multiple of -1.12x. On profitability, it posts a Return on Equity (ROE) of -79.91%, a Return on Assets (ROA) of -46.02%, and a Return on Invested Capital (ROIC) of -230.66%. Per share, it reports EPS of $-1.86, diluted EPS of $-1.86, free cash flow per share of $-1.73, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -45.79% year-over-year and EPS growth of -57.40% year-over-year. On the balance sheet, it maintains a current ratio of 10.98x, a quick ratio of 10.76x, working capital of $87.18M, a debt-to-equity ratio of 0.73x, a debt ratio of 0.42, an interest coverage ratio of -16.55x, free cash flow of $-41.22M (TTM), and net debt of $-43.17M. Figures sourced from SEC EDGAR.
- Market Cap
- $96.86M
- P/E TTM
- -2.19x
- EPS TTM
- $-1.86
- P/B TTM
- 1.68x
- ROE TTM
- -79.91%
- ROA TTM
- -46.02%
- Debt To Equity
- 0.73x
- Free Cash Flow TTM
- $-41.22M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Kalaris Therapeutics, Inc. in?
Kalaris Therapeutics, Inc. (KLRS) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does KLRS trade on?
Kalaris Therapeutics, Inc. (KLRS) trades on the Nasdaq.
Where is Kalaris Therapeutics, Inc. incorporated?
Kalaris Therapeutics, Inc. is incorporated in DE.
When was Kalaris Therapeutics, Inc. (KLRS)'s most recent SEC filing?
Kalaris Therapeutics, Inc. (KLRS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is KLRS's market cap?
Kalaris Therapeutics, Inc. (KLRS) has a market capitalization of $96.86M as of 2026-06-30.
What is KLRS's EPS (earnings per share)?
Kalaris Therapeutics, Inc. (KLRS)'s trailing twelve month EPS is $-1.86 as of 2026-06-30.
What is KLRS's ROE (return on equity)?
Kalaris Therapeutics, Inc. (KLRS)'s trailing twelve month Return on Equity (ROE) is -79.91% as of 2026-06-30.
What is KLRS's ROA (return on assets)?
Kalaris Therapeutics, Inc. (KLRS)'s trailing twelve month Return on Assets (ROA) is -46.02% as of 2026-06-30.
What is KLRS's ROIC (return on invested capital)?
Kalaris Therapeutics, Inc. (KLRS)'s trailing twelve month Return on Invested Capital (ROIC) is -230.66% as of 2023-12-31.
What is KLRS's EV/EBITDA?
Kalaris Therapeutics, Inc. (KLRS)'s trailing twelve month EV/EBITDA is -1.12x as of 2026-06-30.